Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Cancer Investigation is Scopus-indexed (Q3, CiteScore 3.7), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Taylor & Francis Group LLC Philadelphia.
Checked against the index lists dated .
ISSN 0735-7907Verify ISSN ↗1532-4192Verify ISSN ↗
Publisher: Taylor & Francis Group LLC Philadelphia
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Oncology | 230 / 428 | 46th | Q3 |
| Cancer Research | 163 / 233 | 30th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1983–present, best quartile Q3, CiteScore 3.7.
Cancer Investigation is Q3 in Oncology (rank 230 of 428) and Q3 in Cancer Research (rank 163 of 233), by CiteScore 2025.
Cancer Investigation is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 3.7, which places it in quartile Q3 at the 46th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.495, quartile Q3, with an H-index of 97.
Cancer Investigation is published by Taylor & Francis Group LLC Philadelphia. Its print ISSN is 0735-7907 and its online ISSN is 1532-4192.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Cancer Investigation has an h-index of 115 and a 2-year mean of 1.97 citations per paper (OpenAlex). Its Scopus CiteScore is 3.7, quartile Q3. On 2-year citations it ranks #201 of 424 Scopus journals in Oncology.
Cancer Investigation published 92 papers in 2025; its busiest recent year was 2021 with 109. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 100 research articles (2025–2026), authors are most often from China (27%), United States (19.3%) and India (9.2%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 6 retracted papers are recorded (1.4 per 1,000 papers). The Problematic Paper Screener flags 2 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.